Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Uppsala, Sweden – August 7, 2013 – Orexo AB announces that the first patient has been dosed in a new clinical study (ISTART; Induction, STabilization, Adherence, Retention Trial), designed to determine early treatment-efficacy and treatment -adherence to Zubsolv® (buprenorphine and naloxone) sublingual tablets in comparison to conventional buprenorphine/naloxone for the maintenance treatment of opioid dependence.
Help employers find you! Check out all the jobs and post your resume.
Uppsala, Sweden – August 7, 2013 – Orexo AB announces that the first patient has been dosed in a new clinical study (ISTART; Induction, STabilization, Adherence, Retention Trial), designed to determine early treatment-efficacy and treatment -adherence to Zubsolv® (buprenorphine and naloxone) sublingual tablets in comparison to conventional buprenorphine/naloxone for the maintenance treatment of opioid dependence.
Help employers find you! Check out all the jobs and post your resume.
